A multiple-baseline, double-blind evaluation of the effects of trimeprazine tartrate on infant sleep disturbance.

1999 ◽  
Vol 7 (4) ◽  
pp. 502-513 ◽  
Author(s):  
Karyn G. France ◽  
Neville M. Blampied ◽  
Peter Wilkinson
Keyword(s):  
Sleep Disturbance ◽  
Multiple Baseline ◽  
Infant Sleep ◽  
Double Blind

Comparison of Diazepam and Flurazepam in the Treatment of Insomnia in General Practice

1979 ◽  
Vol 7 (5) ◽  
pp. 401-403 ◽  
Author(s):  
Ian MacPhail ◽  
W Alasdair Ogilvie ◽  
C R Purvis
Keyword(s):  
General Practice ◽  
Side Effects ◽  
Sleep Disturbance ◽  
Crossover Study ◽  
Double Blind ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

In a double-blind crossover study in general practice, flurazepam was shown to be significantly better (p<0.001) than diazepam in treating sleep disturbance. Fewer patients reported side-effects on flurazepam.

Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial

2020 ◽  
Vol 76 ◽  
pp. 113-119
Author(s):  
Huajun Xu ◽  
Chujun Zhang ◽  
Yingjun Qian ◽  
Jianyin Zou ◽  
Xinyi Li ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Sleep Disturbance ◽  
Randomised Clinical Trial ◽  
Primary Insomnia ◽  
Middle Aged ◽  
Double Blind

Treating infant sleep disturbance: Does maternal mood impact upon effectiveness?

2010 ◽  
Vol 46 (1-2) ◽  
pp. 29-34 ◽  
Author(s):  
Rudi Črnčec ◽  
Elizabeth Cooper ◽  
Stephen Matthey
Keyword(s):  
Sleep Disturbance ◽  
Infant Sleep ◽  
Maternal Mood

scholarly journals Tu1053 Effects of Omeprazole on Sleep Disturbance: Randomized Multicenter Double-Blind Placebo-Controlled Trial

2014 ◽  
Vol 146 (5) ◽  
pp. S-739
Author(s):  
Masahito Aimi ◽  
Yoshinori Komazawa ◽  
Naoharu Hamamoto ◽  
Yuko Yamane ◽  
Koichiro Furuta ◽  
...  
Keyword(s):  
Sleep Disturbance ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals 0468 A Multiple Dose, Placebo-Controlled, Randomized Double-Blind, Multicenter Study to Investigate Triprolidine in the Treatment of Temporary Sleep Disturbance

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A179-A180
Author(s):  
L Reyner ◽  
J E Miller ◽  
T Shea
Keyword(s):  
Sleep Disturbance ◽  
Daytime Sleepiness ◽  
Multiple Dose ◽  
Dose Range ◽  
Randomized Study ◽  
Sleep Onset ◽  
Primary Diagnosis ◽  
Optimum Dose ◽  
Sleep Onset Latency ◽  
Double Blind

Abstract Introduction American Association of Sleep Medicine guidelines states that the primary goals of the treatment of insomnia are to improve sleep quality and related daytime function. While H1 antihistamines have sedative effects, they are associated with residual daytime sleepiness and an effective dose range for hypnotic effect has hitherto not been established. Triprolidine a first generation antihistamine used to treat allergic rhinitis and the common cold has a mean half-life of 3.2 hours. We evaluated the effect of two doses of triprolodine compared with placebo on sleep onset latency and daytime sleepiness to determine the optimum dose in subjects with temporary sleep disturbance. Methods Multicenter, placebo-controlled, parallel group, double blind, multiple dose, randomized study of 178 patients aged 18 years or above with a primary diagnosis of temporary sleep disturbance. Patients were randomized to one of three groups. Group 1: 2 x placebo tablets; Group 2: 1 x placebo tablet + 1 x 2.5mg triprolidine tablet; Group 3: 2 x 2.5mg triprolodine tablets, taken 20 minutes before intended sleep on three consecutive evenings. Efficacy was measured objectively using the Sleep Disturbance Index using a wrist actimeter and subjectively using the Loughborough Sleep Log and Karolinska Sleepiness Scale. Results Both doses were statistically significantly superior to placebo in terms of quality and duration of sleep and sleep interruptions. No hangover effects or daytime sleepiness were observed with either dose compared to placebo. Patients on the 2.5 mg dose awoke more refreshed than the 5 mg dose. No serious adverse effects observed in any group and anticholinergic events i.e. dry mouth were very low. Conclusion Tripolidine is effective and safe in the treatment of temporary sleep disturbance. The optimum dose is 2.5mg. Support The study was sponsored by Boots Healthcare International.

scholarly journals Infant Sleep Disturbance Is Associated with Preconceptional Psychological Distress: Findings from the Southampton Women's Survey

SLEEP ◽  
2009 ◽  
Vol 32 (4) ◽  
pp. 566-568 ◽  
Author(s):  
Janis Baird ◽  
Catherine M. Hill ◽  
Tony Kendrick ◽  
Hazel M. Inskip
Keyword(s):  
Psychological Distress ◽  
Sleep Disturbance ◽  
Infant Sleep

Help them make it through the night: The behavioural treatment of infant sleep disturbance

1995 ◽  
Vol 20 (1) ◽  
pp. 30-34 ◽  
Author(s):  
Carolyn Lawton ◽  
Neville M. Blampied ◽  
Karyn G. France
Keyword(s):  
Sleep Disturbance ◽  
Sleep Disturbances ◽  
Sleep Onset ◽  
Significant Degree ◽  
Infant Sleep ◽  
Behavioural Treatment ◽  
Onset Delay ◽  
Regular Time ◽  
Clinically Significant ◽  
Night Waking

Sleep disturbances such as bed refusal and resistance, sleep-onset delay, night waking with crying, and unwanted co-sleeping with parents affect 15% to 25% of families during their infant's first two years. A program is described that involves structured pre-bedtime activities, putting the child into his or her own bed awake at a regular time, and responding to subsequent waking and crying with planned ignoring and minimally-arousing checks when necessary. This programme was demonstrated in four families and shown to resolve infant sleep disturbances to a clinically significant degree and to the satisfaction of the parents.

Treating treatment-resistant infant sleep disturbance with combination pharmacotherapy and behavioural family interventions

2006 ◽  
Vol 41 (3) ◽  
pp. 193-204 ◽  
Author(s):  
CHERIN ABDELAAL SELIM ◽  
KARYN G. FRANCE ◽  
NEVILLE M. BLAMPIED ◽  
KATHLEEN A. LIBERTY
Keyword(s):  
Sleep Disturbance ◽  
Infant Sleep ◽  
Treatment Resistant ◽  
Family Interventions ◽  
Combination Pharmacotherapy

Effects of once-daily adjunct quetiapine XR on sleep disturbance in patients with mdd: a pooled analysis from two acute studies

2011 ◽  
Vol 26 (S2) ◽  
pp. 608-608
Author(s):  
M. Bauer ◽  
R.S. McIntyre ◽  
J. Szamosi ◽  
H. Eriksson
Keyword(s):  
Sleep Quality ◽  
Sleep Disturbance ◽  
Pooled Analysis ◽  
Inadequate Response ◽  
Score Change ◽  
Madrs Total Score ◽  
Double Blind ◽  
Disturbance Factor ◽  
Secondary Endpoints ◽  
Post Hoc

IntroductionDisrupted sleep is common in depression.ObjectivesInvestigate effects of adjunct extended release quetiapine fumarate (QTP-XR) on sleep disturbance and quality in patients with MDD and inadequate response to antidepressant (AD) therapy.MethodsData were pooled from two (D1448C00006/D1448C00007) 6-week, double-blind, randomised, placebo (placebo+AD)-controlled studies of adjunct QTP-XR (15 0 mg/day and 300 mg/day). Primary endpoint: MADRS total score change versus placebo+AD. Secondary endpoints (post hoc): change from randomisation in MADRS item 4 (reduced sleep), HAM-D items 4, 5 and 6 (early-, middle- and late-insomnia), sleep disturbance factor (HAM-D items 4+5+6) and sleep quality (PSQI global score). MADRS total score change in patients with baseline HAM-D sleep disturbance factor score > = 4 or < 4 (high and low sleep disturbance, respectively) was evaluated.Results919 patients received adjunct QTP-XR: 150 mg/day (n = 309), 300 mg/day (n = 307), placebo+AD (n = 303). At Week 6, adjunct QTP-XR (both doses) reduced MADRS item 4, HAM-D sleep disturbance factor, HAM-D items 4, 5 and 6 and PSQI global scores from baseline versus placebo+AD (p < 0.001). In patients with baseline HAM-D>=4 (n = 226, 215 and 210, respectively) adjunct QTP-XR (both doses) improved (p< 0.01) MADRS total score versus placebo+AD from Week 1 onward. In patients with baseline HAM-D< 4 (n = 83, 92, 93, respectively) adjunct QTP-XR (both doses) improved (not statistically significantly) MADRS total score versus placebo+AD at Week 6.ConclusionsAdjunct QTP-XR significantly restored sleep and improved sleep quality in patients with MDD and inadequate response to AD. Significant improvement in depressive symptoms was demonstrated with adjunct QTP-XR in patients with MDD and high baseline sleep disturbance. AstraZeneca funded.

Sign in / Sign up

Export Citation Format

Share Document